BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Receives $57 Share Valuation on Potential of NanoAb Platform
BiondVax Pharmaceuticals was recently featured in a research report by Zacks Small-Cap Research The report highlighted BiondVax’s recent achievements, the most notable of which is the proof-of-concept animal trial that delivered positive results suggesting that the company’s anti-COVID-19 NanoAb candidate resulted in milder and shorter illness The company also received support and advice from the Paul Ehrlich Institute (“PEI”), which are viewed as key toward approval for a Phase 1/2a first-in-human clinical trial The report estimates that BiondVax is fully funded for the next 12 months; subsequent to the report’s publication, BiondVax raised an additional $7.3 million net in an…